Why did Agenus stock drop 32% This Morning?
Apr 09, 2022 · Why Agenus Stock Is Crushing It Today - The Motley Fool fool.com - March 3 at 10:39 AM: Why Agenus Stock Is Crushing It Today - Nasdaq nasdaq.com - March 2 at 2:56 PM: Why Agenus Stock Is Crushing It Today finance.yahoo.com - March 2 at 2:56 PM: HC Wainwright & Co. Maintains Buy on Agenus, Raises Price Target to $14 - Benzinga
Why did Agenus get an accelerated approval from the FDA?
Jul 27, 2021 · Price as of April 1, 2022, 8:00 p.m. ET A top company executive is stepping down in the very near future. What happened Even on a generally downbeat day for the stock market, Agenus ( AGEN 4.47% )...
Is the market overreacting to Amgen's contracted guidance?
Oct 22, 2021 · Shares of Agenus ( AGEN 0.51%) dropped more than 32% this morning after the company gave investors bad news regarding its experimental cancer immunotherapy balstilimab. The company has withdrawn...
How much cash does Agenus have?
Aug 04, 2021 · What happened. Amgen ( AMGN -0.97%) shares were trading 6.8% lower late Wednesday following a second-quarter earnings beat that was marred by …
Is AGEN stock a good buy?
Will AGEN stocks go up?
The 3 analysts offering 12-month price forecasts for Agenus Inc have a median target of 8.00, with a high estimate of 14.00 and a low estimate of 7.00. The median estimate represents a +276.47% increase from the last price of 2.13.
Why is AGEN stock up?
In response to the impressive clinical progress of Agenus' anti-cancer checkpoint inhibitor platform, Wainwright raised its 12-month price target on the biotech's shares to $14 ahead of the opening bell this morning.Apr 29, 2022
Is Stellantis a buy now?
Is Agenus a good stock to buy 2021?
What kind of company is Agen?
Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.
Is Ford a buy Zacks?
...
Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 25.08% |
| 2 | Buy | 18.56% |
| 3 | Hold | 10.15% |
| 4 | Sell | 5.79% |
Is Masco stock a buy?
What is Jeep stock called?
A top company executive is stepping down in the very near future
Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles.
What happened
Even on a generally downbeat day for the stock market, Agenus ( NASDAQ:AGEN) was quite a downer on Tuesday. The biotech company's shares fell by just over 6% on the day because of a notable C-suite departure.
So what
Agenus announced in a tersely worded regulatory filing that chief legal and compliance officer Adam Krauss has served notice that he will be vacating his position, effective this Friday, July 30.
Now what
The seemingly abrupt exit by a top legal executive threatens to dampen the company's good momentum Agenus was enjoying its stock performance and its growing reputation among investors.
The biopharma name cautioned shareholders that it's still suffering from a pandemic hangover, but investors should think bigger-picture
James Brumley is former stockbroker with a large Wall Street firm, and a former trading analyst for a small, options-based newsletter. After twenty years of professional experience in and around the market, his approach is one that combines fundamentals, sentiment, and common sense.
What happened
Amgen ( NASDAQ:AMGN) shares were trading 6.8% lower late Wednesday following a second-quarter earnings beat that was marred by lowered full-year guidance.
So what
The biopharma outfit turned $6.5 billion worth of sales into per-share earnings of $4.38 for the three-month stretch ending in June, both up from year-ago figures, and both topping consensus estimates. Analysts were only modeling a profit of $4.09 per share and revenue of $6.46 billion.
Now what
The market's response to contracted guidance is understandable, but perhaps unmerited. Amgen shares have already been a subpar performer of late, currently trading where they were as of November 2019, and now back to breakeven for the year. Most of the company's prospective challenges were already baked in.
Nobody seemed impressed by the company's latest quarterly results
Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles.
What happened
Amgen ( NASDAQ:AMGN) reported its first-quarter results after the market closed on Tuesday, and on Wednesday, its stock really took it on the chin. In late afternoon trading today, it was down by 6.6%.
So what
For the quarter, Amgen's revenue fell 4% year over year to $5.9 billion. This was due to a drop in overall selling prices for the company's products, offset somewhat by increased volume. As for adjusted net profit, it was $2.15 billion ($3.70 per share), representing a steeper fall of 14%.
Now what
One effect of the pandemic is that people have postponed certain nonessential medical procedures. This is one major factor in the declines suffered by many pharmaceutical companies, Amgen included.
